Rokit Healthcare, a regenerative medicine company, is experiencing a surge in stock prices following the announcement of the world's first clinical trials for kidney regeneration.
According to the Korea Exchange, as of 9:37 a.m., Rokit Healthcare's shares rose by 5,050 won (13.76%) to 41,750 won. At one point, the stock increased by 22.75%, reaching 45,200 won.
The announcement that Rokit Healthcare, in collaboration with a leading general hospital in South Korea, has begun the world's first clinical trials for kidney regeneration has reportedly boosted investor sentiment.
Rokit Healthcare stated that it received approval for advanced regenerative medical clinical trials for kidney regeneration from the Institutional Review Board (IRB) of a domestic general hospital the previous day, allowing it to commence human clinical surgeries this month.
The company plans to expedite the rapid approval process for advanced regenerative therapies following the completion of the clinical trials. Earlier, these institutions had received approval for their advanced regenerative medicine research plan from the Ministry of Health and Welfare in May and completed all necessary regulatory procedures.
Rokit Healthcare emphasized, "If this clinical trial is successful, it could change the existing treatment paradigm focused on dialysis and kidney transplants, providing new treatment options for chronic kidney disease patients both domestically and internationally. We will accelerate our research and development efforts to achieve this goal."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.